{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:11:03Z","timestamp":1788477063491,"version":"build-2803163510"},"reference-count":20,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.1248\/bpb.b23-00608","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T22:13:56Z","timestamp":1699568036000},"page":"43-48","source":"Crossref","is-referenced-by-count":7,"title":["Time\u2013Course Changes in Lamotrigine Concentration after Addition of Valproate and the Safety and Long-Term Tolerability of Lamotrigine\u2013Valproate Combination Therapy"],"prefix":"10.1248","volume":"47","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka"},{"name":"Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia<\/i>, <b>49<\/b>, 1239\u20131276 (2008).","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther. Drug Monit.<\/i>, <b>40<\/b>, 526\u2013548 (2018).","DOI":"10.1097\/FTD.0000000000000546"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Johannessen Landmark C, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>16<\/b>, 227\u2013238 (2020).","DOI":"10.1080\/17425255.2020.1724956"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR Jr, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. <i>Neurology<\/i>, <b>63<\/b>, 1022\u20131026 (2004).","DOI":"10.1212\/01.WNL.0000138424.33979.0C"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. <i>Ann. Pharmacother.<\/i>, <b>33<\/b>, 1037\u20131042 (1999).","DOI":"10.1345\/aph.18422"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kwan P, Brodie MJ. Early identification of refractory epilepsy. <i>N. Engl. J. Med.<\/i>, <b>342<\/b>, 314\u2013319 (2000).","DOI":"10.1056\/NEJM200002033420503"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Taing KD, O\u2019Brien TJ, Williams DA, French CR. Anti-epileptic drug combination efficacy in an <i>in vitro<\/i> seizure model\u2014phenytoin and valproate, Lamotrigine and Valproate. <i>PLOS ONE<\/i>, <b>12<\/b>, e0169974 (2017).","DOI":"10.1371\/journal.pone.0169974"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? <i>Epilepsy Res.<\/i>, <b>26<\/b>, 423\u2013432 (1997).","DOI":"10.1016\/S0920-1211(96)01007-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Machado VH, Palmini A, Bastos FA, Rotert R. Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a \u2019proof of concept,\u2019 open label study. <i>Epilepsia<\/i>, <b>52<\/b>, 1303\u20131310 (2011).","DOI":"10.1111\/j.1528-1167.2011.03075.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Thome-Souza S, Valente KD. Valproate and lamotrigine in pediatric patients with refractory epilepsy: after the first year. <i>Pediatr. Neurol.<\/i>, <b>48<\/b>, 436\u2013442 (2013).","DOI":"10.1016\/j.pediatrneurol.2013.01.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y. Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. <i>Biol. Pharm. Bull.<\/i>, <b>35<\/b>, 487\u2013493 (2012).","DOI":"10.1248\/bpb.35.487"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. <i>Br. J. Clin. Pharmacol.<\/i>, <b>33<\/b>, 511\u2013513 (1992).","DOI":"10.1111\/j.1365-2125.1992.tb04079.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. <i>Clin. Pharmacokinet.<\/i>, <b>25<\/b>, 433\u2013443 (1993).","DOI":"10.2165\/00003088-199325060-00003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. <i>Epilepsy Res.<\/i>, <b>42<\/b>, 23\u201331 (2000).","DOI":"10.1016\/S0920-1211(00)00160-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Xu S, Liu L, Chen Y, Liu M, Lu T, Wang H, Liu S, Zhao M, Zhao L. Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>74<\/b>, 583\u2013591 (2018).","DOI":"10.1007\/s00228-018-2414-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yamamoto T, Kubota Y, Murayama H, Ozeki H, Numachi Y, Ikeda A. Appropriate conversion from valproate monotherapy to lamotrigine monotherapy in Japanese women with epilepsy. <i>Epilepsy &amp; Seizure.<\/i>, <b>8<\/b>, 21\u201331 (2016).","DOI":"10.3805\/eands.8.21"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Suzuki T, Mihara K, Nagai G, Kagawa S, Nakamura A, Nemoto K, Kondo T. A high plasma lamotrigine concentration at week 2 as a risk factor for lamotrigine-related rash. <i>Ther. Drug Monit.<\/i>, <b>42<\/b>, 631\u2013635 (2020).","DOI":"10.1097\/FTD.0000000000000733"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M, Schellekens A, de Krom M, Aldenkamp AP. The impact of side effects on long-term retention in three new antiepileptic drugs. <i>Seizure<\/i>, <b>18<\/b>, 327\u2013331 (2009).","DOI":"10.1016\/j.seizure.2008.11.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Wong IC, Mawer GE, Sander JW, Lhatoo SD. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. <i>Epilepsia<\/i>, <b>42<\/b>, 1354\u20131358 (2001).","DOI":"10.1046\/j.1528-1157.2001.02101.x"},{"key":"20","unstructured":"20) FDA Drug Safety Communication. \u201cStudies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease (03 Mar, 2021).\u201d: \u2039https:\/\/www.fda.gov\/media\/147183\/download\u203a."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00608\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:54:29Z","timestamp":1715576069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00608\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00608","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"b23-00608"}}